Longboard Pharmaceuticals, Inc. (LBPH)

NASDAQ: LBPH · IEX Real-Time Price · USD
17.97
-0.04 (-0.22%)
Apr 19, 2024, 2:15 PM EDT - Market open
-0.22%
Market Cap 642.19M
Revenue (ttm) n/a
Net Income (ttm) -54.42M
Shares Out 36.02M
EPS (ttm) -2.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 212,916
Open 17.69
Previous Close 18.01
Day's Range 17.69 - 18.41
52-Week Range 3.60 - 28.15
Beta 1.26
Analysts Strong Buy
Price Target 36.14 (+101.11%)
Earnings Date May 7, 2024

About LBPH

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc.... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 12, 2021
Employees 50
Stock Exchange NASDAQ
Ticker Symbol LBPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for LBPH stock is "Strong Buy." The 12-month stock price forecast is $36.14, which is an increase of 101.11% from the latest price.

Price Target
$36.14
(101.11% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

16 days ago - Business Wire

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

16 days ago - Business Wire

Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates

LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological dis...

5 weeks ago - Business Wire

Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

2 months ago - Business Wire

Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional S...

3 months ago - Business Wire

Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

3 months ago - Business Wire

Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

3 months ago - Business Wire

Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #DEEs--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for ...

3 months ago - Business Wire

Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

3 months ago - Business Wire

Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

5 months ago - Business Wire

Longboard Pharmaceuticals' Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

5 months ago - Business Wire

Longboard Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

5 months ago - Business Wire

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

6 months ago - Business Wire

Longboard Pharmaceuticals to Present at Three Upcoming Investor Conferences in November

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

6 months ago - Business Wire

Longboard Pharmaceuticals Announces Speakers for Investor & Analyst Event in New York on October 11, 2023

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

7 months ago - Business Wire

Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on October 11, 2023

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

7 months ago - Business Wire

Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

8 months ago - Business Wire

Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

8 months ago - Business Wire

Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies

LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological dis...

8 months ago - Business Wire

Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

9 months ago - Business Wire

Longboard Pharmaceuticals to Present at Upcoming Investor Conferences

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

9 months ago - Business Wire

Longboard Pharmaceuticals to Participate in Fireside Chat with Cantor on Friday, June 30, 2023

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

10 months ago - Business Wire

Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological dis...

1 year ago - Business Wire

Longboard Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines ...

1 year ago - Business Wire

Longboard Pharmaceuticals Reports Full Year 2022 Financial Results and Key Corporate Initiatives

SAN DIEGO--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neu...

1 year ago - Business Wire